ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 274 filers reported holding ARRAY BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is 0.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $460,000 | -4.4% | 9,924 | -49.8% | 0.05% | -57.5% |
| Q1 2019 | $481,000 | +80.1% | 19,762 | +5.4% | 0.11% | +73.8% |
| Q4 2018 | $267,000 | -36.1% | 18,752 | -31.7% | 0.06% | -20.7% |
| Q3 2018 | $418,000 | -6.7% | 27,475 | +2.9% | 0.08% | -7.9% |
| Q2 2018 | $448,000 | +41.8% | 26,700 | +37.9% | 0.09% | +34.8% |
| Q1 2018 | $316,000 | +73.6% | 19,368 | +36.2% | 0.07% | +83.3% |
| Q4 2017 | $182,000 | +127.5% | 14,222 | +59.3% | 0.04% | +200.0% |
| Q1 2017 | $80,000 | -5.9% | 8,930 | -8.2% | 0.01% | -7.7% |
| Q4 2016 | $85,000 | -11.5% | 9,725 | -31.5% | 0.01% | 0.0% |
| Q3 2016 | $96,000 | +242.9% | 14,200 | +151.5% | 0.01% | +550.0% |
| Q4 2013 | $28,000 | -40.4% | 5,647 | -25.8% | 0.00% | -50.0% |
| Q3 2013 | $47,000 | +11.9% | 7,612 | -16.8% | 0.00% | 0.0% |
| Q2 2013 | $42,000 | – | 9,152 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |